Beyond Apoptosis: Ferroptosis as the Missing Link in Modern Disease Management

Abstract Ferroptosis represents a revolutionary paradigm in cell death biology, characterized as an iron-dependent, nonapoptotic form of regulated cell death driven by lipid peroxidation and glutathione depletion. Unlike traditional cell death mechanisms, ferroptosis operates through unique molecular pathways involving system xc¯ dysfunction, glutathione peroxidase 4 (GPX4) GPX4 inactivation, and iron-catalyzed oxidative damage to polyunsaturated fatty acid-containing phospholipids. This distinctive process has emerged as a critical determinant in diverse pathological conditions, spanning from hematological malignancies, including acute myeloid leukemia and multiple myeloma, to extensive nonhematological disorders encompassing neurodegenerative diseases, cardiovascular pathologies, renal dysfunction, metabolic syndromes, and organ-specific conditions. The therapeutic implications of ferroptosis are particularly compelling, offering dual opportunities for both disease prevention through ferroptosis inhibition in degenerative conditions and therapeutic exploitation through ferroptosis induction in proliferative disorders. Current therapeutic strategies range from iron chelation and antioxidant enhancement for neuroprotection to targeted ferroptosis induction for cancer treatment, with emerging nanotechnology applications enhancing specificity and efficacy. The integration of ferroptosis modulators with conventional therapies demonstrates significant synergistic potential, while personalized approaches utilizing biomarker-guided strategies promise optimized therapeutic outcomes. As our understanding of tissue-specific ferroptotic mechanisms deepens, this iron-dependent pathway represents a transformative frontier in precision medicine, offering unprecedented opportunities for targeted interventions across the spectrum of human disease.